COVID
| Primary Site |
Sponsor/Study ID
NCT#
|
Protocol Description |
Eligibility |
| COVID Symptoms |
Regeneron
R10933-10987-COV-2066
NCT04426695
|
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike
(S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Hospitalized
Patients with COVID-19 |
-
Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen
-
Cohort 1: O2 saturation >93% on low-flow oxygen via nasal cannula, simple face
mask, or other similar device
For Both Cohorts:
- ≥18 years of age
- Positive molecular test for COVID 19 ≤72 hours prior to randomization
- Onset of Symptoms ≤10 days
- Hospitalized due to COVID-19
- No pregnant or breastfeeding women
- No prior convalescent plasma
- Willing to use contraception at least 6 months after the last dose
|
| COVID Respiratory Symptoms |
Duke University
NCT04399889
|
Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal
Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) |
- ≥18 years of age
- Positive molecular testing for COVID-19
- Criteria for Acute Respiratory Symptoms
- No pregnant or breastfeeding women
- No signs of multi-organ failure
|
| COVID Respiratory Symptoms |
The Ohio State University
PreVent
NCT04466683
|
Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for
Patients with SARS-CoV-2 Pneumonia |
- ≥50 years of age
- Hospitalized due to COVID-19
- Onset of symptoms ≤ 9 days
- Diagnosis of COVID related pneumonia
- Not on ventilator use
- No female pregnant or breastfeeding
|